Real Endpoints (RE) is pleased to announce that its RxScorecard™ IT platform supports MSK Cancer Center’s DrugAbacus
Online PR News – 22-June-2015 – Westport, CT – ‘DrugAbacus’, a Comparative Cancer Drug Pricing Platform Powered by Real Endpoints’ RxScorecard™ is Launched
Westport, CT, June 22, 2015 – Real Endpoints (RE) is pleased to announce that its RxScorecard™ is the information technology platform supporting Memorial Sloan Kettering Cancer Center’s DrugAbacus - an interactive tool for considering the basis of cancer drug prices. Conceived by Dr. Peter B. Bach, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering (MSK), DrugAbacus was launched at www.drugabacus.org.
MSK’s DrugAbacus generates a dollar-value for cancer drugs available in the United States (beginning in 2001 with Gleevec) based on a user’s settings for six different domains of potential value including the treatment’s survival benefit, side effects, and the incidence of the condition targeted. Memorial Sloan Kettering licensed the Real Endpoints RxScorecard™ platform for research purposes so users can generate “Abacus prices” and compare them with actual prices of these drugs at the time of launch in a visual and intuitive format.
“We believe RxScorecard™ is the only tool available that provides a 360 degree comparison of the multiple components of a drug’s value in an independent, objective and systematic approach. We developed the IT platform to make it very easy for users to access our analysis, and are delighted that Dr. Bach selected this platform for DrugAbacus,” said Julie Eskay Eagle, RE’s Vice President of Product Development.
“If you're deciding which drugs to put on a formulary or to prescribe, you need to know what you're getting for the price,” said Roger Longman, CEO of Real Endpoints. “There are websites that compare drug prices -- but nothing that objectively compares multiple elements of value simultaneously, except RxScorecard™.”
RxScorecard™ has been used to compare drug regimens for patients with the Hepatitis C virus (HCV), Chronic Obstructive Pulmonary Disease (COPD) and lipid disorders. Recently RE clinicians and statisticians also conducted a study that compared the value of the three leading drug regimens for adjuvant breast cancer. This study was selected for presentation at this year’s 51st Annual meeting of the American Society of Clinical Oncology (Abstract #6602), an event of international importance for cancer physicians and researchers.
About Real Endpoints
Real Endpoints is a health care information and analytics company that prepares healthcare providers, payers and pharmaceutical companies for the value-based healthcare economy.
Learn more at: